Quality Investor
MarketsPortfolioEvidenceTestedCompareWatchlistAbout 

Kiniksa Pharmaceuticals International, plc

Rank #27HypergrowthWatchlistCompare with other stocks

KNSA · Nasdaq · Healthcare

Kiniksa Pharmaceuticals International, plc (KNSA) — Rank #27 by gross profitability (GP/assets 0.73) · ROE 9.7% · Piotroski F-Score 7 / 9.

As-of 2026-10-30 · CIK 0001730430 · all metrics point-in-time as of the filing date.

About

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.

Show more

The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024.

Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Filer Category
Large accelerated filer
Fiscal Year End
December 31

Company Snapshot

P/S is the primary valuation lens — earnings are reinvested, not available for P/E.

Market Cap

—

P/E (annual)

—

P/S (annual)

—

P/B

—

P/OCF (annual)

—

Shareholder Yield

—

Employees

366

Industry

Drug Manufacturers - Specialty & Generic

Exchange

Nasdaq

11/12

Flags passed

KNSA passes 11/12 quality flags

1 caution to review

  • CAUTION
    Dilution above 2%

    Annual share count increase exceeds 2%. May be acceptable for high-growth companies funding talent via stock compensation

  • PASS
    Gross margin holding
  • PASS
    FCF not negative from investment
  • PASS
    Disclosure consistent
  • PASS
    Revenue not declining
  • PASS
    Operating margin holding
  • PASS
    Free cash flow intact
  • PASS
    Passes safety gate
  • PASS
    Balance sheet stable
  • PASS
    No competitive retreat
  • PASS
    SBC not compressing margin
  • PASS
    No valuation convergence

Strengths Revenue growth accelerating · Sequential beat (rev + EPS)

A count of the 12 warning flags that could be evaluated. Unweighted: colour follows the worst flag.

Quality Profile

Profitability

1/1 pass
GP / assets
0.73
Return on equity
9.7%
Gross margin trend
PASS

Safety

1/1 pass
Balance-sheet safety
PASS
Debt / equity
0.36
Current ratio
3.79×
Net cash
$468.09M

Cash Flow

3/3 pass
Positive FCF
PASS
Cash-backed earnings
PASS
Accruals healthy
PASS
SBC / revenue
5.5%

Growth

1/2 pass
Revenue growth
60.1%
Piotroski F-Score
7 / 9
Share dilution
10.6%

Revenue growth and the path to profitability (margin trend) are the primary reads at this stage.

Profitability

Does it make money well?

No warning flags · GP/assets 0.73

Gross profitability (GP / assets)

0.73

Primary signal (Novy-Marx).

3rd of 12 SIC 2834 peers

Return on equity

9.7%

Gross margin

88.5%

2nd of 12 SIC 2834 peers

Revenue growth (YoY)

60.1%

Gross margin improving

Margin trend vs prior year.

PASS

Operating Leverage

2022202320242025
Revenue vs COGS
Revenue vs OpEx
Op. Income vs Revenue

Growth

Revenue CAGR (3Y)

45.5%

Revenue CAGR (5Y)

—

Earnings CAGR (3Y)

-31.5%

FCF CAGR (3Y)

—

Cash Flow Health

Is the cash real?

No warning flags · FCF 131% above net income

Free cash flow

$136.42M

Operating cash flow minus capex.

Positive free cash flow

PASS

FCF vs net income

131.2%

(FCF − net income) ÷ |net income|. Positive: cash above earnings. Negative: below.

FCF not below net income

Fails when free cash flow is below net income (yellow flag).

PASS

Accruals healthy

Cash-backed earnings.

PASS

SBC / revenue

5.5%

Stock-based comp intensity.

Balance Sheet Strength

Can it survive a storm?

Caution: Dilution above 2% · net cash $468.09M, F-Score 7/9

Balance-sheet safety

Composite anti-fragile check.

PASS

Debt / equity

0.36

1st of 12 SIC 2834 peers (best = lowest)

Current ratio

3.79×

2nd of 12 SIC 2834 peers

Quick ratio

3.14×

Net cash

$468.09M

Cash & equivalents minus total debt.

Piotroski F-Score

7 / 9

Fundamental-strength score (0-9).

Valuation

Is the price reasonable?

No warning flags

Capital allocation quality

Composite score

2.7 / 5

Fair
Share count trend
10.6%0/5 Weak
Buyback timing
N/AN/A
Dividend growth consistency(non-payer or broken streak)
0 yr3/5 Good
Net debt trajectory(deleveraging)
22.3%5/5 Strong

Lifecycle Phase History

20212025
Startup
Hypergrowth

Price History

KNSA+523.4% · +44.1% CAGRSPY+82.9% · +12.8% CAGR

View full financial statements →

Source filings on SEC EDGAR: 10-K annual reports · 10-Q quarterly reports